Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics announced after the close of the market on Tuesday that its third quarter revenues grew 38 percent year over year, surpassing the consensus Wall Street estimate.

For the three months ended Sept. 30, the Parsippany, New Jersey-based firm posted $5.8 million in revenues compared to $4.2 million in the year-ago period. It beat the analysts' average estimate of $5.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.